Freeze-dried plasma stability under prehospital field conditions.
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
27
05
2019
revised:
08
08
2019
accepted:
13
08
2019
pubmed:
1
10
2019
medline:
9
6
2020
entrez:
1
10
2019
Statut:
ppublish
Résumé
This study evaluated the effect of routine, uncontrolled, Israeli field storage conditions on the stability and efficacy of Lyo-Plas N freeze-dried plasma (FDP). We evaluated clotting factors V, VIII, and XI; proteins S and C; fibrinogen; partial thromboplastin time (PTT); antithrombin III (ATIII); von Willebrand factor (VWF); and international normalized ratio (INR) in FDP stored at 4°C, 25°C, and 40°C for 6 and 12 months, as well as FDP returned from field units after uncontrolled storage for 15 months (manufacturer's shelf life). After reconstitution, clotting factor levels were compared to those of freshly supplied FDP doses. At 4°C for 12 months, factor V decreased slightly. At 25°C, average fibrinogen and factor V content were significantly lower at both periods, and INR was higher after 12 months. At 40°C, all samples were out of normal range in at least one clotting factor after 6 or 12 months. After field storage for 15 months, fibrinogen, factors V and XI, PTT, and protein S were significantly decreased, and INR increased. However, these levels were still within laboratory norms. Statistically significant difference in clotting factors compared to laboratory normal range was found in INR (higher) and factor V (lower). Our data show minimal decreases in clotting factors in FDP after storage under field conditions, when compared to laboratory normal ranges. Along with the many advantages of FDP, this supports its use at the point of injury under battlefield conditions, despite uncontrolled storage environments. Under controlled storage conditions at 4°C, shelf life could possibly be extended, although further study is required.
Sections du résumé
BACKGROUND
This study evaluated the effect of routine, uncontrolled, Israeli field storage conditions on the stability and efficacy of Lyo-Plas N freeze-dried plasma (FDP). We evaluated clotting factors V, VIII, and XI; proteins S and C; fibrinogen; partial thromboplastin time (PTT); antithrombin III (ATIII); von Willebrand factor (VWF); and international normalized ratio (INR) in FDP stored at 4°C, 25°C, and 40°C for 6 and 12 months, as well as FDP returned from field units after uncontrolled storage for 15 months (manufacturer's shelf life).
METHODS AND MATERIALS
After reconstitution, clotting factor levels were compared to those of freshly supplied FDP doses.
RESULTS
At 4°C for 12 months, factor V decreased slightly. At 25°C, average fibrinogen and factor V content were significantly lower at both periods, and INR was higher after 12 months. At 40°C, all samples were out of normal range in at least one clotting factor after 6 or 12 months. After field storage for 15 months, fibrinogen, factors V and XI, PTT, and protein S were significantly decreased, and INR increased. However, these levels were still within laboratory norms. Statistically significant difference in clotting factors compared to laboratory normal range was found in INR (higher) and factor V (lower).
CONCLUSIONS
Our data show minimal decreases in clotting factors in FDP after storage under field conditions, when compared to laboratory normal ranges. Along with the many advantages of FDP, this supports its use at the point of injury under battlefield conditions, despite uncontrolled storage environments. Under controlled storage conditions at 4°C, shelf life could possibly be extended, although further study is required.
Substances chimiques
Factor V
9001-24-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3485-3490Informations de copyright
© 2019 AABB.
Références
Eastridge BJ, Mabry RL, Seguin P, et al. Death on the battlefield (2001-2011): implications for the future of combat casualty care. J Trauma Acute Care Surg 2012;73(6 Suppl 5):S431-S437.
Holcomb JB, McMullin NR, Pearse L, et al. Causes of death in U.S. special operations forces in the global war on terrorism: 2001-2004. Ann Surg 2007;245:986-91.
Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 2015;313:471-82.
Butler FK, Holcomb JB, Schreiber MA, et al. Fluid resuscitation for hemorrhagic shock in tactical combat casualty care: TCCC guidelines change 14-01-2 June 2014. J Spec Oper Med 2014;14:13-38.
Henrikson HH, Rahbar E, Bear LA, et al. Pre-hospital transfusion of plasma in hemorrhaging trauma patients independently improves hemostatic competence and acidosis. Scand J Trauma Resusc Emerg Med 2016;24:1-6.
Pusateri AE, Given MB, Schreiber MA, et al. Dried plasma: state of the science and recent developments. Transfusion 2016;56:128-39.
Sperry JL, Guyette JB, Brown MH, et al. Prehospital plasma during air medical transport in trauma patients at risk for hemorrhagic shock. N Engl J Med 2018;379:315-26.
Barelli S, Alberio L. The role of plasma transfusion in massive bleeding: protecting the endothelial glycocalyx? Front Med Lausanne 2018;5:91.
Shlaifer A, Siman-Tov M, Radomislensky I, et al. Pre hospital administration of freeze dried plasma, is it the solution for trauma casualties? J Trauma Acute Care Surg 2017;83:675-82.
Schmidt PJ. The plasma wars: a history. Transfusion 2012;52(Suppl 1):2S-4S.
Bux J, Dickhörner D, Scheel E. Quality of freeze-dried (lyophilized) quarantined single-donor plasma. Transfusion 2013;53:3203-9.
Glassberg E, Nadler R, Gendler S, et al. Freeze-dried plasma at the point of injury: from concept to doctrine. Shock 2013;40:444-50.
De Winter S, Vanbrabant P, Vi NT, et al. Impact of temperature exposure on stability of drugs in a real-world out-of-hospital setting. Ann Emerg Med 2013;62:380-7 e1.
Kupper TE, Schraut B, Rieke B, et al. Drugs and drug administration in extreme environments. J Travel Med 2006;13:35-47.
https://www.pharmaguideline.com/2010/12/different-climatic-zones-for-stability.html
http://cz.werfen.com/productsservices/hemostasisdiagnostics/reagents/thrombophilia.aspx
http://cz.werfen.com/products-services/hemostasis-diagnostics/reagents/general-screening-and-anticoagulant-monitoring.aspx
https://www.sheba.co.il/laboratory_division_book
Martinaud C, Civadier C, Ausset S, et al. In vitro hemostatic properties of French lyophilized plasma. Anesthesiology 2012;117:339-46.
Litvinov R, Weisel JW. What is the biological and clinical relevance of fibrin? Semin Thromb Hemost 2016;42:333-43.
Rourke C, Curry N, Khan S, et al. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost 2012;10:1342-51.
Fries D, Martini WZ. Role of fibrinogen in trauma-induced coagulopathy. Br J Anaesth 2010;105:116-21.
Shuja F, Shults C, Duggan M, et al. Development and testing of freeze-dried plasma for the treatment of trauma-associated coagulopathy. J Trauma 2008;65:975-85.
Bolliger D, Gorlinger K, Tnaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology 2010;113:1205-19.